Legend Biotech (LEGN)

Executive Summary

Legend Biotech (NASDAQ: LEGN) is a global cell therapy company best known for CARVYKTI (cilta-cel), a BCMA-targeted CAR-T therapy for multiple myeloma developed in collaboration with Janssen. CARVYKTI is approved in the U.S., EU, and China and represents the primary revenue driver. Beyond myeloma, Legend is advancing a deep pipeline of autologous and allogeneic cell therapies targeting hematologic malignancies, solid tumors, and autoimmune diseases. Key pipeline assets include LCAR-AIO for multiple sclerosis (Phase 1), LUCAR-G39D for B-cell non-Hodgkin lymphoma (Phase 1), and LUCAR-B68 for multiple myeloma (Phase 1). The company also explores NK cell therapies and earlier-stage candidates. With a strong commercial foundation, expanding manufacturing capabilities, and a broad clinical pipeline, Legend is well-positioned in the cell therapy space. The company's strategic focus on both oncology and autoimmune indications diversifies its risk and growth potential.

Upcoming Catalysts (preview)

• Q3 2026CARVYKTI label expansion to earlier lines of multiple myeloma (CARTITUDE-4)75% success
• Q4 2026Initial clinical data readout for LCAR-AIO in autoimmune diseases (e.g., multiple sclerosis Phase 1)45% success
• Q4 2026Manufacturing scale-up milestones or new partnership announcement for allogeneic platform60% success